Page last updated: 2024-12-09

2-(2-chlorophenyl)-5-(methylamino)-4-oxazolecarbonitrile

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(2-chlorophenyl)-5-(methylamino)-4-oxazolecarbonitrile is a chemical compound with the molecular formula C11H8ClN3O. It's not commonly known by this name, but it's often referred to as **compound 1** or **the oxazole derivative** in scientific literature.

**Why is it important for research?**

This compound exhibits interesting biological activity, specifically as a **potent and selective inhibitor of the enzyme HDAC6** (histone deacetylase 6).

**What is HDAC6?**

HDAC6 is an enzyme involved in regulating cellular processes by removing acetyl groups from proteins. It plays a role in:

* **Protein degradation:** HDAC6 helps in the degradation of misfolded or damaged proteins, protecting cells from stress.
* **Microtubule stability:** It affects the stability of microtubules, which are important for cell division and transport.
* **Inflammation:** HDAC6 is involved in the regulation of inflammatory responses.

**Why is inhibiting HDAC6 important?**

Inhibiting HDAC6 has shown promise in treating a variety of diseases, including:

* **Cancer:** HDAC6 inhibitors can promote cell death in cancer cells and enhance the effectiveness of chemotherapy.
* **Neurodegenerative diseases:** By promoting protein degradation and protecting neurons, HDAC6 inhibitors may be helpful in treating diseases like Alzheimer's and Parkinson's.
* **Inflammatory diseases:** HDAC6 inhibitors can reduce inflammation by modulating immune responses.

**The significance of 2-(2-chlorophenyl)-5-(methylamino)-4-oxazolecarbonitrile:**

This specific compound demonstrates **high potency** in inhibiting HDAC6, making it a valuable tool for research. It's being investigated as a potential therapeutic agent for various diseases.

**Current research:**

Researchers are exploring the potential of 2-(2-chlorophenyl)-5-(methylamino)-4-oxazolecarbonitrile as a **lead compound** for developing new and improved HDAC6 inhibitors with even greater efficacy and safety profiles.

**Note:** While promising, it's important to remember that this compound is still under investigation and its potential therapeutic benefits are yet to be fully established.

Cross-References

ID SourceID
PubMed CID661078
CHEMBL ID1379223
CHEBI ID112394

Synonyms (15)

Synonym
AKOS002686264
MLS000077618 ,
smr000041794
NCGC00019817-01
CHEBI:112394
STK896343
2-(2-chlorophenyl)-5-(methylamino)-1,3-oxazole-4-carbonitrile
AB00384695-04
NCGC00019817-02
HMS2301F24
CHEMBL1379223
Q27192498
2-(2-chlorophenyl)-5-(methylamino)-4-oxazolecarbonitrile
SR-01000001725-2
sr-01000001725
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
1,3-oxazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
LuciferasePhotinus pyralis (common eastern firefly)Potency21.33130.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency8.91250.01846.806014.1254AID624417
ClpPBacillus subtilisPotency15.84891.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency23.10930.004110.890331.5287AID504467
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency31.62280.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency0.35480.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency89.12510.035520.977089.1251AID504332
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]